LATEST NEWS

London, UK – 04 August 2010


Proximagen announces sale of sabcomeline.


Read more...

Annual Report 2009


Proximagen’s 2009 Annual Report has recently been published.


Download PDF...

INVESTORS

Investor Relations


Our investor relations centre is provided to give you convenient access to company information.


Read more...

Share Price

Proximagen Group plc (Ticker: PRX) is listed on the London Stock Exchange’s Alternative Investment Market.


View Share Price...

SCIENCE

Proximagen's commitment to science is fundamental. We strive for true scientific innovation, breaking new ground in treatment.


View our Pipeline...

Therapeutic Areas

Proximagen's vision is to become one of the world's leading companies developing therapeutics for patients suffering from diseases of the CNS.


Read more...